The THxID® BRAF Mutation Analysis assay is for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin embedded (FFPE) melanoma tissue. It is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with dabrafenib, and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib.
THXID® is a registered trademark of bioMerieux.

There are several key genes recurrently mutated in melanoma. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the BRAF, CD274, CDK4, HRAS, KIT, KRAS, NF1, and NRAS genes is determined using next-generation sequencing (NGS) technology.